|
Home Page
About Us
Investors
Inventors
Portfolio
3DR Laboratories, LLC
AllTranz Inc.
ApoVax, Inc.
Edumedics, LLC
EndoProtech, Inc.
Eyevation, LLC
Gnarus Systems, Inc.
ImmunoTheragnostics Incorporated
Intrepid Bioinformatics, Inc.
PGxl Laboratories, LLC
RhinoCyte, Inc.
TrackFive Diagnostics, Inc.
Contact Us
Privacy Policy
|
|
|
|
Portfolio - EndoProtech, Inc.
| Incorporated: |
|
August 2005
|
| Contacts: |
|
Claudio Maldonado, Ph.D., Co-Founder and President
Gustavo A. Perez-Abadia, M.D., Co-Founder, Vice President and Treasurer
|
| Description: |
|
EndoProtech's technology facilitates the rapid targeted delivery and long term display of clinically relevant bio-therapeutics on the surface of the vascular endothelium, permitting close monitoring and protection of vascular surfaces. EndoProtech is developing and commercializing unique therapies which have application in the fields of organ transplantation and invasive cardiovascular surgery.
Ischemia Reperfusion Injury (IRI) associated with organ transplant and numerous cardiovascular procedures initiates a cataclysmic cascade which compromises the function and integrity of the vascular endothelium; a significant contributor to graft dysfunction, low cardiac output syndrome and overall peri and post-operative morbidity and mortality. There are no accepted therapies for IRI; EndoProtech is leveraging its platform technology to develop effective targeted modalities to address this unmet medical need.
In 2008 over 28,000 organ transplants were completed, with additional 106,000 individuals awaiting transplant. First-year costs associated with solid organ transplants totaled more than $9 billion; more than half of this amount was attributed to post-transplant care costs.
According to a 2009 American Heart Association update over 450,000 coronary artery bypass graft (CABG) procedures are performed annually. The U.S. revenue potential for a treatment directed at preventing post-CABG complication is significant. For example, a reduction of one post-op cardiac care unit day from hospitalization of patients undergoing CABG would result in an overall savings of $1.2 billion.
EndoProtech researchers were awarded a $1M NIH STTR Phase II grant in 2008. In 2009 the company was awarded $270,000 through the Kentucky Cabinet for Economic Development SBIR-STTR matching funds program. This funding is supporting pivotal safety and efficacy studies. Lead product formulation and stability studies are ongoing.
|
|
|
